摘要
变应性鼻炎(allergic rhinitis,AR)是一种以IgE介导为主的鼻黏膜慢性炎症,患病率逐年提高。变应原特异性免疫治疗(allergen specific immunotherapy,AIT)已被证实在治疗AR方面效果显著。患者在规范疗程结束后,通常能取得满意的临床缓解。目前,临床主要以sIgE/tIgE评价AR患者免疫治疗前的过敏严重程度,但对于AIT治疗期间的疗效评价尚无公认的生物标志物。本文基于免疫细胞参与诱导AIT免疫耐受形成的相关机制,对近年来AR相关免疫细胞标志物在AIT的疗效评估方面的最新进展作一综述,以期在免疫治疗期间为AR患者提供更加全面的评估依据。
Allergic rhinitis(AR)is a chronic inflammation of nasal mucosa mediated by IgE,which prevalence is increasing year by year.Allergen immunotherapy(AIT)has been proved to be effective in the treatment of AR.Patients can usually achieve satisfactory clinical remission after the standard course of treatment.At present,sIgE/tIgE is mainly used to evaluate the severity of allergy in patients with AR before immunotherapy,but there is no recognized biomarker for evaluating the efficacy of AIT.Based on the mechanism that immune cells participate in the formation of immune tolerance during AIT,this paper reviews the latest progress of immune cell markers in allergic rhinitis for the evaluation of the efficacy of AIT in recent years,in order to provide a more comprehensive evaluation basis for AR patients during immunotherapy.
作者
李瀚达
张怡
陶泽璋
LI Handa;ZHANG Yi;TAO Zezhang(Department of Otolaryngology Head and Neck Surgery,Renmin Hospital of Wuhan University,Wuhan,430060,China;Department of Otolaryngology Head and Neck Surgery,Beijing Chaoyang Hospital,Capital Medical University)
出处
《临床耳鼻咽喉头颈外科杂志》
CAS
CSCD
北大核心
2024年第3期251-255,260,共6页
Journal of Clinical Otorhinolaryngology Head And Neck Surgery
基金
国家自然科学基金资助项目(No:8187041108、8197040163)。
